MedTrace Logo

Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients

NCT05842486 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2023-05-06

No results posted yet for this study

Summary

The aim of this non-interventional secondary use of data study is to evaluate hematological response in patients with paroxysmal nocturnal hemoglobinuria and anemia in the 6-month period after initiation of anti-C5 antibody treatment using real-world data obtained from multiple datasets. The results will be used to contextualize results from the APPOINT-PNH (NCT04820530) trial with iptacopan.

Conditions

Interventions

OTHER

Anti-C5 antibody treatment

Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)

Sponsors & Collaborators

  • Leeds Cancer Centre at St. James's University Hospital

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-18
Primary Completion
2023-03-01
Completion
2023-03-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05842486 on ClinicalTrials.gov